Frequently Asked Questions for the Illuminating the Druggable Genome Implementation Phase

Updated 1/30/17 

We appreciate your interest in the Illuminating the Druggable Genome Program Request for Applications (RFA-RM-16-024, RFA-RM-16-025, and RFA-RM-16-026) and hope that you and your team will choose to submit an application. In order to maximize your chances of success, we would like to provide some guidance that may be helpful as you put the finishing touches on your application.

General Questions

1. What is the Common Fund?

2. Should I contact the Program Official before applying for one of the RFAs?

3. What should I do if I believe there are understudied proteins that are not on the list in the RFA?

4. What should I do if I believe a protein is not understudied and should not be on the list in the RFA?

5. As an NIH intramural researcher, am I eligible to apply for this program, directly or in conjunction with co-applicants?

6. Can I be a PI on more than one application? What about more than one DRGC application?

7. Can an Investigator from a foreign institution serve as a PI on a multi-PI application?

8. I am not a present IDG awardee- do I have the same chance of getting an award as a present IDG awardee?

9. Who will build and host the IDG Portal – the KMC or the RDOC?

10. Which component of the IDG will be responsible for generating and tracking semi-annual milestones on data deposition, resources generated, and how they are accessible?

11. Who will analyze and deposit data generated by the DRGCs?

12. Are there any updates to the NIH IDG collaboration with the Knockout Mouse Phenotyping (KOMP2) Program?

DRGC RFA Questions

1. For the DRGCs, what if I want to study all three protein families instead of just one?

2. For the DRGCs, is it allowable to have different deliverables for different subclasses of the protein family?

3. For the DRGCs, can we request up to $1.6M per year direct costs (excluding F&A)?

4. For the DRGCs, is it acceptable to use an approach that explores more members of protein family than just the understudied proteins in the list?

5. Can you clarify the phrase “simple knock-out or overexpression studies are not considered sufficiently modulatory for the long-term goals of this FOA” in the DRGC RFA?

6. Can the DRGCs be multi-institutional?

RDOC RFA Questions

1. What is the role of the RDOC in generating web content, tools, etc. for the IDG Portal?

KMC RFA Questions

1. How important and relevant is the pilot phase KMC to the new RFA?

2. How important are specific tasks to be detailed in the application?

3. Is it true that the KMC will include the entire proteome and not just the IDG relevant target classes?

Budget Questions

1. What budget information should be included in applications to the KMC and DRGC FOAs for the 10% of the total direct costs to fund collaborations with other IDG awardees that advance the overall goals of the Consortium?

This page last reviewed on January 31, 2017